Markers, kits and methods for assessment of lymph node metastasis in papillary thyroid carcinoma

By jointly detecting miR-616-3p, miR-1285-5p and IgG N-glycan biomarkers GP4, GP10, GP13, and GP24, a multidimensional biomarker model was constructed, solving the problem of non-invasive assessment of lymph node metastasis in papillary thyroid carcinoma and achieving highly accurate diagnosis and prognostic assessment.

CN121518655BActive Publication Date: 2026-07-21SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
Filing Date
2026-01-16
Publication Date
2026-07-21

AI Technical Summary

Technical Problem

Existing technologies are not very effective in non-invasive assessment methods for the diagnosis of lymph node metastasis in papillary thyroid carcinoma. Single biomarkers are difficult to achieve accurate metastasis risk assessment, and there is a lack of mature multi-dimensional combined biomarker systems and dedicated detection kits.

Method used

We employed a combined detection method using miRNA biomarkers miR-616-3p and miR-1285-5p, and IgG N-glycan biomarkers GP4, GP10, GP13, and GP24. Serum exosomal miRNAs were extracted and detected by qRT-PCR, combined with IgG N-glycosylation detection, and a logistic regression model was constructed for risk assessment.

Benefits of technology

It significantly improves the diagnostic accuracy and specificity of lymph node metastasis in papillary thyroid carcinoma, provides a scientific basis for early diagnosis and intervention, and reduces the disease burden.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121518655B_ABST
    Figure CN121518655B_ABST
Patent Text Reader

Abstract

The application discloses a kind of markers for thyroid papillary carcinoma lymph node metastasis evaluation, kit, belong to sugar chemistry technical field.The marker includes: two kinds of miRNA biomarker and IgG N-glycan;Wherein, the miRNA biomarker is miR-616-3p and miR-1285-5p;The IgG N-glycan is GP4, GP10, GP13 and GP24.The application is constructed biomarker model by joint detection miR-616-3p, miR-1285-5p, GP4, GP10, GP13 and GP24 six key indicators, effectively overcome multiple collinearity problem, AUC value reaches 0.930, significantly surpasses the general efficiency level of clinical routine diagnostic method, provides high-precision judgment tool for PTC LNM clinical decision.This value shows extremely high discriminant ability;Specificity is strong, the model constructed based on miRNA and initial glycan internal correlation analysis significantly related with PTC LNM, with good specificity and reliability.
Need to check novelty before this filing date? Find Prior Art